Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - flecainide acetate 100 mg - tablet - 100 mg - flecainide acetate 100 mg - flecainide

Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - flecainide acetate 150,012 mg - prolonged-release capsule, hard - 150 mg - flecainide acetate 150.012 mg - flecainide

Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - flecainide acetate 100,008 mg - prolonged-release capsule, hard - 100 mg - flecainide acetate 100.008 mg - flecainide

Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - flecainide acetate 200,016 mg - prolonged-release capsule, hard - 200 mg - flecainide acetate 200.016 mg - flecainide

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

golden state medical supply, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets usp are also indicated for the prevention of: - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecai

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide is indicated for the prevention of -     paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   -     paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. flecainide is also indicated for the prevention of -     documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician, are life-threatening. use of flecainide for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide should not be used in patients with recent myocardial infarction (see boxed warnings ). use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death. flecainide is contraindicated in patients with preexisting second- or third degree av block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. flecainide is also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of    —   paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms    —   paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of    —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets, usp are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarr